Neoadjuvant Immunotherapy in Melanoma – The New Frontier Available to Purchase

Neoadjuvant immunotherapy is gathering pace, particularly in melanoma. A recent study of pembrolizumab and HDI not only further supports the safety and activity of neoadjuvant anti–PD-1 based immunotherapy but also highlights neoadjuvant therapy as a solid platform for drug development that is likely to become a standard-of-care in the near future.

See related article by Najjar et al., p. 4195